N/A N=68 China Antiretroviral Treatment Adherence for Life
HIV Infections
Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 SpaceOAR System RWS in China
Localized T1-T2 Prostate Cancer
Primary: Primary Effectiveness Endpoint — 15.1 mm
N/A N=98 Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
HIV-1 Infections
Primary: Evolution of the HIV Viral Response — 0; 51; 0; 3 participant
N/A N=55 Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China
Rheumatoid Arthritis
Primary: Median Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score at Week 24 — -0.3 units on a scale — p==0.0002
N/A N=1,390 Real-world Study of Dedifferentiated Liposarcoma Patients in China
Dedifferentiated Liposarcoma
Primary: Cohort 1: Overall Survival — 13.4; 11.9; 8.1 months
N/A N=21,240 A Safety Study For Prevenar 13 Among Chinese Children
Seizures · Urticaria and Angioedema · Apnea
Primary: Incidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After Dose 1 — NA; NA Events per 1000 person-days
N/A N=1,507 Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants
N/A N=22 To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
Benign Prostatic Hyperplasia (BPH)
Primary: International Prostate Symptom Score (IPSS) Change From Baseline to the Last Follow-up Date, Anywhere Between Month 3 - Month 6 Post Rezūm Procedure. — 14.9 scores on a…
N/A N=5,115 Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting
Coronary Artery Disease, Hypercholesterolemia, Hypertension
Primary: Achievement Rate for Low Density Lipoprotein-Cholesterol (LDL-C) for Overall — 0.79; 0.67; 0.83; 0.57 Ratio
N/A N=30 A RWS of the FARAPULSE in A Chinese Population With PAF
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Acute Procedural Success — 30 Participants
N/A N=120 China Adherence Through Technology Study
Medication Adherence
Primary: Difference in Proportion of Subjects Who Achieve >/= 95% Adherence — 55; 29 Participants
N/A N=2,482 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Angioplasty · Chronic Coronary Occlusion · Stent Thrombosis
Primary: Number of Participants With Incidence of the Composite Rate of Cardiac Death and Any Myocardial Infarction (MI) (Including Q-wave and Non-Q-wave) — 33 Participants
Phase 4 N=36 Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
Stable Coronary Heart Disease (CHD)
Primary: IPA on Day 1 — 27.09; 25.87; 33.34; 57.20 % IPA
N/A N=2,002 XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Angioplasty · Cardiovascular Disease · Coronary Artery Disease
Primary: Number of Participants With Cardiac Death and All Myocardial Infarction (MI) (Q-wave and Non-Q Wave) Composite Endpoint — 7 Participants
N/A N=228 Real World Data on Gi(l)Otrif® Dose Adjustment
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Patients With Adverse Drug Reactions (ADR) by Severity Class. — 21.02; 21.13; 44.59; 57.75 Percentage of patients (%)
N/A N=18,995 Observational Registry for Basal Insulin Treatment Study (ORBIT)
Diabetes
Primary: To Assess the Change in HbA1c During the 6 Months Follow-up. — 2.1 percent
N/A N=20 Observation of ImageReady™ MR Conditional Defibrillation System in China
Arrhythmia
Primary: The Percent of Participants Who Were MR Scan-Related ImageReady System Complication -Free — 100 percentage of participants
N/A N=300 A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
Immunogenicity, Vaccine
Primary: Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG) by Cohort — 1.55; 0.12; 0.42; 0.07 microgram per milliliter (µg/mL)
Phase 4 N=2,004 Brilinta DaYu Study
Acute Coronary Syndrome
Primary: Bleeding Events — 17; 27; 93; 426 Participants
N/A N=1,537 Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
Type 2 Diabetes Mellitus
Primary: Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and…
N/A N=885 Rosuvastatin Adherence App Study in China
Dyslipidemia · Hyperlipidemia
Primary: Duration of Treatment — 156.7; 146.0 days — p=0.0019
N/A N=103 SYNERGY China: Assess SYNERGY Stent in China
Cardiovascular Diseases
Primary: Technical Success Rate — 98.1 percentage of participants
N/A N=58 China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
Aortic Stenosis · Symptomatic Aortic Stenosis · Aortic Regurgitation
Primary: All-cause Mortality — 0 Participants
N/A N=10 Observation of ImageReady™ MR Conditional Pacing System in China
Arhythmia · Atrioventricular Heart-block · Chronic Bundle Branch or Branch Block
Primary: Percentage of Participants Without Complications at MRI Visit + 1 Month. — 100 percentage of paticipants
N/A N=70 The Development of a Mobile-based App to Increase Uptake of Pre-Exposure Prophylaxis (PrEP) by Men Who Have Sex With Men in China
HIV · Pre-exposure Prophylaxis
Primary: Change in Intention to Use PrEP Score — 0.19; 0.00; 0.57; -0.09 score on a scale — p=0.85
N/A N=11,001 Real World Glycemic Effectiveness of Linagliptin
Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories — -0.51; -0.65; -0.59; -0.43 Percentage (%)
N/A N=299 Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
Lung Cancer
Primary: Body Mass Index (BMI): All Asian Participants — 22.6; 23.1; 26.4 Kilogram per square meter
N/A N=13 Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Renal Cell Carcinoma
Primary: Duration of Axitinib Treatment — 15.2 months
Phase 4 N=50 DynamX Bioadaptor Hong Kong Registry
Coronary Artery Disease
Primary: Acute Device Success — 49 Participants
N/A N=250 Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
Glabellar Lines
Primary: Percentage of Participants in Each Response Category for Overall Participant Satisfaction at Visit 6, Assessed by the Subject Satisfaction Questionnaire — 71.1; 28.9; 0…